Bergen, Norway, February 25, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases today announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with … Read more
Bergen, Norway, 18 February 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2024 on Wednesday 26 February 2025. BerGenBio’s senior management team will provide a business update at 10:30 am CET. The presentation will webcast … Read more
Bergen, Norway, January 7, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio … Read more
BERGEN, Norway, November 26, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that the Company will present at the DNB Nordic Healthcare Conference today in Oslo, Norway at 14:45-15:05 CET. Chief Executive Officer Olav Hellebø will provide a business update including … Read more
Bergen, Norway, November 20, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024. Mr. Hellebø brings three decades of experience in the pharmaceutical … Read more
Bergen, Norway, November 13, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m Study Ph1b enrollment … Read more
Bergen, Norway, 5 November 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2024 on Wednesday 13 November 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To … Read more
Bergen, Norway, 10 October 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces today that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. “On behalf of the Board of … Read more
Bergen, Norway,10 October 2024 – An Extraordinary general meeting of BerGenBio ASA was virtually held today 10 October 2024 at 10.00 CEST. All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 19 September 2024 as further set out in the minutes from the extraordinary general meeting attached … Read more
Ph1b data support safety, predictable PK and adequate plasma exposure Bergen, Norway, October 7, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.